Bioregenx (BRGX) Non-Current Receivables (2023 - 2024)
Bioregenx's quarterly Non-Current Receivables came in at $454766.0 in Q1 2024, little changed quarter-over-quarter from $454371.0 in Q4 2023.
Bioregenx has reported Non-Current Receivables for 2 years, with the latest figure at $454766.0 in Q1 2024.
- For the quarter ending Q1 2024, Non-Current Receivables changed N/A year-over-year to $454766.0; the trailing twelve-month figure through Mar 2024 stood at $454766.0 (changed N/A YoY), and the FY2023 full-year result was $454371.0, changed N/A from the prior year.
- Non-Current Receivables for Q1 2024 stood at $454766.0, roughly flat from $454371.0 in the prior quarter.
- The five-year high for Non-Current Receivables was $454766.0 in Q1 2024, with the low at $454371.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 30.85 Bn | 24.28 Bn | 622.47 Mn | - |
| 2 | BrightSpring Health Services | 12.29 Bn | 11.41 Bn | 482.22 Mn | 40.77 Mn |
| 3 | Healthequity | 7.80 Bn | 7.48 Bn | 256.31 Mn | - |
| 4 | Hinge Health | 4.82 Bn | 4.51 Bn | 154.23 Mn | - |
| 5 | Doximity | 4.21 Bn | 3.46 Bn | 125.97 Mn | - |
| 6 | Waystar Holding | 4.18 Bn | 4.03 Bn | 268.04 Mn | - |
| 7 | 10x Genomics | 3.78 Bn | 3.24 Bn | 106.18 Mn | - |
| 8 | Privia Health | 2.65 Bn | 2.28 Bn | 595.71 Mn | - |
| 9 | Omnicell | 1.95 Bn | 1.78 Bn | 140.36 Mn | - |
| 10 | Bioregenx | - | - | 348,288.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 454,766.00 |
| Dec 31, 2023 | 454,371.00 |